Timing, Sequencing of Immunotherapy Combination May Improve Mesothelioma ResponseMesotheliomaHelp.org (blog)In September, MesotheliomaHelp reported on researchers taking a closer look at immune cells to help identify those patients who may respond best… Continue reading
Bennington Banner |
Baby gene therapy study offers hope for fatal muscle disease
Bennington Banner Dr. Jerry Mendell of the Center for Gene Therapy at Nationwide Children’s Hospital in Columbus, Ohio. Mendell led a small study of gene therapy in babies born with a usually fatal neuromuscular disease and reported Nov. 1 that the experiment extended … |
Bennington Banner |
Baby gene therapy study offers hope for fatal muscle disease
Bennington Banner Dr. Jerry Mendell of the Center for Gene Therapy at Nationwide Children’s Hospital in Columbus, Ohio. Mendell led a small study of gene therapy in babies born with a usually fatal neuromuscular disease and reported Nov. 1 that the experiment extended … |
|
Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William Blair
StreetInsider.com William Blair analyst, Tim Lugo, reiterated his Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) after the company announced the FDA had approved an investigational new drug (IND) application for its GALGT2 gene therapy program … Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene …GlobeNewswire (press release) |
pharmaphorum |
Novartis files CAR–T in Europe in broader use than Gilead rival
pharmaphorum Chimeric antigen receptor T–cell (CAR-T) therapies are one-off treatments that involve harvesting a patient’s T–cells, and genetically reprogramming them to fight cancer. Trial data so far show they offer a complete response – a complete absence of … Novartis files CAR–T therapy in EuropePharmaTimes Novartis seeks European approval for cell therapy KymriahReuters |
CBS News |
Playing God: “We are in the midst of a genetic revolution”
CBS News Dr. Emmanuelle Charpintier at the Max Planck Institute in Germany is one half of the duo that discovered CRISPR‘s gene-cutting abilities. She and her research partner, Jennifer Doudna of UC-Berkeley, manipulated a naturally occurring defense system in … |